ATE258188T1 - Retro-, inverso-, und retro-inverso synthetische peptidanaloge - Google Patents

Retro-, inverso-, und retro-inverso synthetische peptidanaloge

Info

Publication number
ATE258188T1
ATE258188T1 AT93918788T AT93918788T ATE258188T1 AT E258188 T1 ATE258188 T1 AT E258188T1 AT 93918788 T AT93918788 T AT 93918788T AT 93918788 T AT93918788 T AT 93918788T AT E258188 T1 ATE258188 T1 AT E258188T1
Authority
AT
Austria
Prior art keywords
retro
inverso
synthetic peptide
analogues
peptide analogs
Prior art date
Application number
AT93918788T
Other languages
English (en)
Inventor
Alfio Comis
Peter Fischer
Margaret Isabel Tyler
Original Assignee
Deakin Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deakin Res Ltd filed Critical Deakin Res Ltd
Application granted granted Critical
Publication of ATE258188T1 publication Critical patent/ATE258188T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93918788T 1992-08-27 1993-08-27 Retro-, inverso-, und retro-inverso synthetische peptidanaloge ATE258188T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL437492 1992-08-27
PCT/AU1993/000441 WO1994005311A1 (en) 1992-08-27 1993-08-27 Retro-, inverso-, and retro-inverso synthetic peptide analogues

Publications (1)

Publication Number Publication Date
ATE258188T1 true ATE258188T1 (de) 2004-02-15

Family

ID=3776390

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918788T ATE258188T1 (de) 1992-08-27 1993-08-27 Retro-, inverso-, und retro-inverso synthetische peptidanaloge

Country Status (14)

Country Link
US (1) US6261569B1 (de)
EP (1) EP0667786B1 (de)
JP (1) JP4116072B2 (de)
KR (1) KR950702839A (de)
CN (1) CN1091138A (de)
AT (1) ATE258188T1 (de)
AU (1) AU667578B2 (de)
BR (1) BR9306984A (de)
CA (1) CA2143823C (de)
DE (1) DE69333397T2 (de)
HU (1) HUT71860A (de)
NZ (1) NZ255256A (de)
OA (1) OA10129A (de)
WO (1) WO1994005311A1 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
AU699757B2 (en) * 1994-02-25 1998-12-17 Bioclones (Pty) Ltd Synthetic inverso or retro-inverso T-cell epitopes
FR2717081B1 (fr) * 1994-03-14 1996-06-21 Centre Nat Rech Scient Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
US5814316A (en) * 1994-08-05 1998-09-29 Wisconsin Alumni Research Foundation Compound to mimick a naturally occurring peptide's effect
FR2737209B1 (fr) 1995-07-25 1997-09-19 Bio Merieux Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c
IT1277057B1 (it) * 1995-12-11 1997-11-04 Tecnogen Scpa Peptidi antigenici migliorati
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
EP0947525A1 (de) 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe
CA2349290A1 (en) * 1998-11-19 2000-06-02 Elan Corporation, Plc Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US7449544B2 (en) * 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
EP1174506A1 (de) * 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminales Erns-Peptide und Analoge davon
DE10054055A1 (de) * 2000-10-31 2002-05-23 Nmi Univ Tuebingen Verfahren zur Analyse von Proteinen
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
IL140881A0 (en) * 2001-01-14 2002-02-10 Katz Emil Israel A method for identification and quantification of proteins in a biopsy or other tissue sample and a kit for use thereof
AU2002259130A1 (en) * 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) * 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CN101415724B (zh) * 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
EP1663199B1 (de) * 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) * 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US7259145B2 (en) * 2004-07-07 2007-08-21 The Research Foundation Of State University Of New York Mechanically activated channel blocker
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006013552A2 (en) * 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
EP1793816B1 (de) * 2004-08-19 2012-01-04 Tel Aviv University Future Technology Development L.P. Zusammensetzungen zur behandlung von amyloid-assoziierten erkrankungen
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
EP1826199A1 (de) 2006-02-27 2007-08-29 Technische Universität Wien Modifizierte Aminosäuren
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US7674772B2 (en) * 2006-03-31 2010-03-09 Queen's University At Kingston Compositions and methods for treating atherosclerosis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
MX2011004082A (es) 2008-10-17 2011-10-14 Dana Farber Cancer Inst Inc Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102348720A (zh) 2009-03-09 2012-02-08 雷蒙特亚特特拉维夫大学有限公司 预防和治疗神经退行性疾病的组合物和方法
CA2768149A1 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
RU2013126706A (ru) 2010-11-15 2014-12-27 Рамот Ат Тель-Авив Юниверсити Лтд. Дипептидные аналоги для лечения состояний, ассоциированных с образованием амилоидных фибрилл
US9211313B2 (en) 2011-01-14 2015-12-15 The Research Foundation Of State University Of New York Methods and compound to inhibit Ca2+ permeable cation conductance
WO2012135081A2 (en) 2011-03-25 2012-10-04 Children's Medical Center Corporation Lin28-mediated control of let-7 biogenesis
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
MX365403B (es) 2012-01-09 2019-05-31 Serpin Pharma Llc Peptidos y metodos para usarlos.
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US9572855B2 (en) 2013-03-11 2017-02-21 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics
US9789156B2 (en) 2013-03-11 2017-10-17 Dana-Farber Cancer Institute, Inc. Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
US11084860B2 (en) 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
PT3524618T (pt) 2013-03-15 2023-06-06 Gladiator Biosciences Inc Domínios gla como agentes de marcação
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CN104744564B (zh) * 2015-03-13 2017-07-28 天津托普泰克生物科技有限公司 抗乙型肝炎病毒x蛋白多肽药物
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP4194001B1 (de) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
AU2016317726B2 (en) 2015-08-28 2022-05-26 Serpin Pharma, Llc Methods for treatment of diseases
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
US10774122B2 (en) 2017-03-21 2020-09-15 The Regents Of The University Of Michigan ERG targeted therapy
JP2020533976A (ja) 2017-09-05 2020-11-26 グラディエーター バイオサイエンシーズ インコーポレイテッド エキソソームを標的化する方法
PT3737399T (pt) * 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー, インコーポレイテッド 改善されたアンタゴニスト的抗ヒトcd40モノクローナル抗体
WO2020055824A1 (en) 2018-09-10 2020-03-19 Board of Regents, The University of the Texas System Dry powder formulation of caveolin-1 peptides and methods of use thereof
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
CN111233975A (zh) * 2018-11-28 2020-06-05 复旦大学 可靶向整合素的多肽mn及其在制备肿瘤靶向药物中的应用
WO2020185826A1 (en) 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
JP2024539242A (ja) 2021-10-22 2024-10-28 ラング セラピューティクス,エルエルシー 慢性腎疾患の治療のための改変カベオリン-1ペプチド
CN115343485B (zh) * 2022-10-18 2023-01-06 天津德祥生物技术股份有限公司 血型抗原三糖偶联物在血型抗体检测中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010260A (en) * 1975-07-28 1977-03-01 Ayerst Mckenna & Harrison Ltd. Derivatives of retro-enantio-somatostatin, intermediates therefor, and process therefor
CA1040623A (en) * 1975-08-28 1978-10-17 Hans U. Immer Derivatives of retro-enantio-somatostatin, intermediates therefor and process therefor
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
IT1164225B (it) * 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
IT1206339B (it) * 1984-01-13 1989-04-14 Anic Spa Analoghi retro-invertiti esapeptidici c-terminali della sostanza p.
IT1178789B (it) * 1984-12-21 1987-09-16 Assorenti Peptidi retro-invertiti analoghi del potenziatore della bradichinina bpp 5a
IT1184164B (it) * 1985-03-19 1987-10-22 Eniricerche Spa Triptidi ad azione ipotensiva e procedimento per la loro sintesi
US4709017A (en) * 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
AU617088B2 (en) * 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
IT1216908B (it) 1987-03-19 1990-03-14 Eniricerche Spa Analoghi retro-inversi della timopentina e dei suoi frammenti, il metodo per la loro sintesi ed il loro impiego per la preparazionedi composizioni farmaceutiche.
FR2615104B1 (fr) * 1987-05-14 1989-08-18 Centre Nat Rech Scient Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme
JP2921574B2 (ja) 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのt細胞のエピトープ
EP0333356A3 (de) * 1988-03-04 1990-12-19 Biogen, Inc. Hirudin-Peptide
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
IT1226552B (it) 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
US5000952A (en) 1988-08-02 1991-03-19 The Board Of Trustees Of The Leland Stanford, Jr. University Polypeptide pertussis toxin vaccine
FI904329A0 (fi) 1988-12-05 1990-09-03 Biogen Inc Foerfaranden och kompositioner foer inhibering av tronbocytaggregation.
IT1227907B (it) * 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
IT1230733B (it) * 1989-06-30 1991-10-29 Eniricerche Spa Analoghi della timopentina retro invertita a tutti i legami, il metodo per la loro sintesi ed il loro impiego per la preparazione di composizioni farmaceutiche.
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
GB9005829D0 (en) 1990-03-15 1990-05-09 Proteus Biotech Ltd Synthetic polypeptides
GB9100468D0 (en) 1991-01-09 1991-02-20 Proteus Molecular Design Improvements in and relating to hormones
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
WO1993011155A1 (en) 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments of prion proteins
GB9208428D0 (en) 1992-04-16 1992-06-03 Proteus Molecular Design Synthetic polypeptides
IL106436A0 (en) * 1992-07-22 1993-11-15 Proteus Molecular Design Synthetic polypeptides and their use
WO1994004565A2 (en) * 1992-08-26 1994-03-03 Proteus Molecular Design Limited Ipnv vaccine
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)

Also Published As

Publication number Publication date
JPH08500829A (ja) 1996-01-30
HUT71860A (en) 1996-02-28
CA2143823A1 (en) 1994-03-17
EP0667786A4 (de) 1997-08-06
WO1994005311A1 (en) 1994-03-17
DE69333397D1 (de) 2004-02-26
EP0667786B1 (de) 2004-01-21
JP4116072B2 (ja) 2008-07-09
OA10129A (en) 1996-12-18
NZ255256A (en) 1997-02-24
KR950702839A (ko) 1995-08-23
DE69333397T2 (de) 2004-12-09
EP0667786A1 (de) 1995-08-23
US6261569B1 (en) 2001-07-17
AU4934693A (en) 1994-03-29
HU9500571D0 (en) 1995-04-28
AU667578B2 (en) 1996-03-28
BR9306984A (pt) 1999-01-12
CA2143823C (en) 2005-07-26
CN1091138A (zh) 1994-08-24

Similar Documents

Publication Publication Date Title
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
EA200100425A1 (ru) Новые способы терапевтической вакцинации
IL91007A0 (en) Synthetic vaccine against aids virus
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
ES8801372A1 (es) Un metodo para preparar una vacuna contra el virus de la influenza equina.
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
ATE71534T1 (de) Vakzine.
NZ220500A (en) Recombinant felv polypeptide; vaccine and expression vectors
DE3884672D1 (de) Ein synthetisches Nonapeptid zur Verwendung als Adjuvant.
EP0496787A4 (en) Novel infectious bursal disease virus
SE8700466D0 (sv) Vaccines against melanoma
OA08974A (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties